IL2 and metastatic melanoma: In the phase 2 clinical trial, patients with unresectable or metastatic melanoma that was stage IIIC or IV who had confirmed radiologic progression and who had been previously treated with checkpoint inhibitor(s) and BRAF ± MEK targeted agents received lifileucel with IL-2.